ESC 365 - Novel Designer Natriuretic Peptide (ZD100) in Human Resistant-Like Hypertension

Back

ESC Premium Access

Novel Designer Natriuretic Peptide (ZD100) in Human Resistant-Like Hypertension - A First in Human Study

Session: Resistant hypertension

Topic: Treatment of hypertension

Speaker: Professor H. Chen (Rochester, US)

Event: ESC Congress 2016

Congress Presentation

About the speaker

Professor Horng Chen

Mayo Clinic, Rochester (United States of America)

0 follower

4 more presentations in this session

State of the art in treatment of resistant hypertension.

Speaker: Professor R. Schmieder (Erlangen, DE)

Access

Slides

Video

The role of adding spironolactone and renal denervation in true resistant hypertension. one-year outcomes of randomized study.

Speaker: Doctor J. Rosa (Nymburk, CZ)

SYMPLICITY HTN-3 screen failure patient cohort analysis

Speaker: Doctor R. Waksman (Washington, DC, US)

Future direction for research in management of resistant hypertension.

Speaker: Professor A. Pathak (Monaco, MC)

Access

Slides

Video

Access the full session

Resistant hypertension

Speakers: Professor H. Chen, Professor R. Schmieder, Doctor J. Rosa, Doctor R. Waksman, Professor A. Pathak

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

Novel Designer Natriuretic Peptide (ZD100) in Human Resistant-Like Hypertension - A First in Human Study

About the speaker

Professor Horng Chen

4 more presentations in this session

State of the art in treatment of resistant hypertension.

The role of adding spironolactone and renal denervation in true resistant hypertension. one-year outcomes of randomized study.

SYMPLICITY HTN-3 screen failure patient cohort analysis

Future direction for research in management of resistant hypertension.

Access the full session

Resistant hypertension

About the event

ESC Congress 2016

ESC 365 is supported by